New antibody drug aims to block Brain-Attacking autoantibodies
NCT ID NCT07093333
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2a trial tests a drug called ART5803 in 30 adults with anti-NMDAR encephalitis or related psychiatric disease. The drug is a lab-made antibody designed to block harmful autoantibodies from attacking brain receptors. The study focuses on safety and tolerability, with early signs of effectiveness also being measured.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ART5803 (a lab-made antibody that blocks harmful autoantibodies from attacking brain receptors)
What this could lead to
If successful, this could point toward a targeted treatment for anti-NMDAR encephalitis and related psychiatric conditions, potentially reducing symptoms and improving quality of life.
What could go wrong
This is an early Phase 2a study with only 30 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••